Board discusses enforcement factors for cost‑growth targets; debate centers on high‑cost drugs

The Office of Health Care Affordability asked the board to advise which factors should be considered when entities exceed the state's spending growth targets, with particular attention to whether high‑cost drugs should justify limited or broad relief. Staff summarized the statute’s enforcement considerations — including an entity’s contribution to excess cost growth, actions that erode access or quality, controllability of cost drivers and whether circumstances fall outside the entity’s control. The statute also permits a waiver for “reasonable factors outside the entity’s control,” such as changes in state or federal law, or extraordinary events. Why this matters: the office must weigh systemic pressures (for example, new expensive therapies or federal funding changes) against the mandate to restrain spending growth. The board must decide whether to treat specific high‑cost drugs as a routine mitigating factor (which could expand exceptions) or to preserve narrow, evidence‑based pathways when a drug meaningfully and unusually affects a single entity’s costs. Board members and public speakers split on approach. Some members urged narrow application: board member Ian Lewis said exceptions should be “rare and surgically used,” arguing that broad waivers would undermine the targets. Others noted HR 1 and other federal changes are substantial and will differently affect institutions depending on payer mix and local exposure. Stakeholders described the complexity of pharmaceutical pricing and the supply chain. Health plans, physician organizations and hospitals told staff they have varying degrees of influence over drug acquisition and administration costs; consumer advocates pointed to markups and hospital charge practices as drivers of excessive spending. In public comment, a representative of UniteCare Health, Ivana Krychenovich, cited local examples of hospitals charging hundreds — and in some itemized examples more than 50,000 — times Medicare for certain drug lines and urged the office to analyze hospital markups. Board discussion touched on two paths: (1) a narrowly defined process that would allow an entity to demonstrate a material, documented, uncontrollable drug‑cost shock for a limited set of drugs (for example, a brand new cell or gene therapy with rapid uptake at a few centers); or (2) a broader approach that would allow the office to revisit the statewide target if a class of drugs caused systemwide cost pressure (for example, mass adoption of a new therapy class). Several board members said the broader response — changing the target itself — is preferable to entity‑level waivers. Staff will continue analysis, including using HPD and hospital financial data to identify specific drug codes, measure their contribution to spending changes and consider comparison metrics (for example, commercial vs. Medicare revenue ratios). The office said it will return with recommendations on operationalizing any drug‑cost mitigation rules.